Isolation and Characterization of Human Immunodeficiency Virus Type 1 Resistant to the Small-Molecule CCR5 Antagonist TAK-652
Authors:
Open Access
- 1 February 2007
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (2) , 707-715
Abstract
TAK-652, a novel small-molecule chemokine receptor antagonist, is a highly potent and selective inhibitor of CCR5-using (R5) human immunodeficiency virus type 1 (HIV-1) replication in vitro. Since TAK-652 is orally bioavailable and has favorable pharmacokinetic profiles in humans, it is considered a promising candidate for an entry inhibitor of HIV-1. To investigate the resistance to TAK-652, peripheral blood mononuclear cells were infected with the R5 HIV-1 primary isolate KK and passaged in the presence of escalating concentrations of the compound for more than 1 year. After 67 weeks of cultivation, the escape virus emerged even in the presence of a high concentration of TAK-652. This virus displayed more than 200,000-fold resistance to TAK-652 compared with the wild type. The escape virus appeared to have cross-resistance to the structurally related compound TAK-779 but retained full susceptibility to TAK-220, which is from a different class of CCR5 antagonists. Furthermore, the escape virus was unable to use CXCR4 as a coreceptor. Analysis for Env amino acid sequences of escape viruses at certain points of passage revealed that amino acid changes accumulated with an increasing number of passages. Several amino acid changes not only in the V3 region but also in other Env regions seemed to be required for R5 HIV-1 to acquire complete resistance to TAK-652.Keywords
This publication has 31 references indexed in Scilit:
- Recent advances of CCR5 antagonistsCurrent Opinion in HIV and AIDS, 2006
- Analysis of Binding Sites for the New Small-Molecule CCR5 Antagonist TAK-220 on Human CCR5Antimicrobial Agents and Chemotherapy, 2005
- TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in HumansAntimicrobial Agents and Chemotherapy, 2005
- Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 AntagonistAntimicrobial Agents and Chemotherapy, 2005
- Treatment for Adult HIV InfectionJAMA, 2004
- Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 InhibitorJournal of Virology, 2004
- CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and DiseaseAnnual Review of Immunology, 1999
- Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4Journal of Experimental Medicine, 1997
- Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected IndividualsJournal of Experimental Medicine, 1997
- Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp!20 geneNature, 1991